- Home
- PODC vs HOWL Comparison
PODC vs HOWL Comparison
Compare PODC & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PODC
- HOWL
- Stock Information
- Founded
- PODC 2013
- HOWL 2017
- Country
- PODC United States
- HOWL United States
- Employees
- PODC N/A
- HOWL N/A
- Industry
- PODC
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- PODC
- HOWL Health Care
- Exchange
- PODC Nasdaq
- HOWL Nasdaq
- Market Cap
- PODC 44.1M
- HOWL 47.1M
- IPO Year
- PODC N/A
- HOWL 2021
- Fundamental
- Price
- PODC $1.90
- HOWL $1.36
- Analyst Decision
- PODC
- HOWL Strong Buy
- Analyst Count
- PODC 0
- HOWL 3
- Target Price
- PODC N/A
- HOWL $8.33
- AVG Volume (30 Days)
- PODC 105.3K
- HOWL 554.2K
- Earning Date
- PODC 08-12-2025
- HOWL 08-07-2025
- Dividend Yield
- PODC N/A
- HOWL N/A
- EPS Growth
- PODC N/A
- HOWL N/A
- EPS
- PODC N/A
- HOWL N/A
- Revenue
- PODC $52,119,000.00
- HOWL $1,143,000.00
- Revenue This Year
- PODC $19.39
- HOWL N/A
- Revenue Next Year
- PODC $23.41
- HOWL N/A
- P/E Ratio
- PODC N/A
- HOWL N/A
- Revenue Growth
- PODC 20.36
- HOWL N/A
- 52 Week Low
- PODC $1.10
- HOWL $0.60
- 52 Week High
- PODC $2.94
- HOWL $4.18
- Technical
- Relative Strength Index (RSI)
- PODC 42.50
- HOWL 60.96
- Support Level
- PODC $1.92
- HOWL $1.25
- Resistance Level
- PODC $2.06
- HOWL $1.44
- Average True Range (ATR)
- PODC 0.21
- HOWL 0.10
- MACD
- PODC -0.04
- HOWL 0.02
- Stochastic Oscillator
- PODC 12.93
- HOWL 68.89
About PODC PodcastOne Inc.
PodcastOne Inc is a podcast platform and publisher that makes its content available to audiences via all podcasting distribution platforms, including its website, its PodcastOne app, Apple Podcasts, Spotify, Amazon Music, and more.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.